文献速递产科母胎医学

基于抗磷脂抗体谱的原发性抗磷脂综合征产科结局:PREGNANTS研究

Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
PubMed 文献 · Am J Obstet Gynecol · 2017-01-30

PREGNANTS研究为多中心回顾性队列研究,纳入750例单胎原发性抗磷脂综合征妊娠,均自早孕期接受低剂量阿司匹林和预防性低分子肝素治疗。抗β2糖蛋白-I单独阳性者活产率最低(47.7%),且子痫前期、胎儿生长受限和死产发生率最高;多重抗体阳性者活产率显著低于单一抗体阳性者(40.9% vs 56.6%)。

要点

  • 抗β2糖蛋白-I单独阳性者活产率47.7%,低于抗心磷脂抗体单独阳性者56.3%和狼疮抗凝物单独阳性者79.6%(P<.01)。
  • 多重抗体阳性者较单一抗体阳性者活产率降低(40.9% vs 56.6%,校正OR 0.71,95%CI 0.51-0.90)。
  • 三重阳性者即使接受低剂量阿司匹林和预防性低分子肝素治疗,活产率仅30%。

核心结论

  • 在单胎原发性抗磷脂综合征妊娠中,抗心磷脂抗体是最常见的单一抗体,但抗β2糖蛋白-I单独阳性与最低活产率和最高子痫前期、胎儿生长受限及死产发生率相关。
  • 多重抗体阳性者产科并发症风险增高、活产率降低;三重阳性者接受治疗后活产率仅30%。

研究设计与样本

  • PREGNANTS研究为多中心、回顾性队列研究,纳入750例单胎原发性抗磷脂综合征妊娠。
  • 诊断和分类基于2006年国际修订标准;所有孕妇至少满足1项临床标准、至少1种抗磷脂抗体阳性,并自早孕期接受低剂量阿司匹林和预防性低分子肝素治疗。

主要发现

  • 活产率:狼疮抗凝物单独阳性79.6%,抗心磷脂抗体单独阳性56.3%,抗β2糖蛋白-I单独阳性47.7%,双重阳性且狼疮抗凝物阴性43.3%,三重阳性30.0%。
  • 多重抗体阳性 vs 单一抗体阳性:活产率40.9% vs 56.6%(校正OR 0.71,95%CI 0.51-0.90);无严重特征的子痫前期54.5% vs 34.8%(校正OR 1.56,95%CI 1.22-1.95);伴严重特征的子痫前期22.7% vs 13.8%(校正OR 1.66,95%CI 1.19-2.49);胎儿生长受限53.6% vs 40.8%(校正OR 2.31,95%CI 1.17-2.61);死产36.4% vs 21.7%(校正OR 2.67,95%CI 1.22-2.94)。
  • 单一抗体阳性组中,抗β2糖蛋白-I阳性 vs 抗心磷脂抗体阳性 vs 狼疮抗凝物阳性:活产率47.7% vs 56.3% vs 79.6%(P<.01);无严重特征子痫前期47.7% vs 34.1% vs 11.1%(P<.01);伴严重特征子痫前期17.2% vs 14.4% vs 0%(P=.02);胎儿生长受限48.4% vs 40.1% vs 25.9%(P<.01);死产29.7% vs 21.2% vs 7.4%(P<.01)。
  • 多重抗体阳性组中,三重阳性 vs 双重阳性且狼疮抗凝物阴性:活产率30% vs 43.3%(校正OR 0.69,95%CI 0.22-0.91);胎儿生长受限70.0% vs 50.0%(校正OR 2.40,95%CI 1.15-2.99)。

关键数值与推荐

  • 原发性抗磷脂综合征诊断和分类基于2006年国际修订标准。
  • 纳入标准:至少1项临床标准、至少1种抗磷脂抗体(抗心磷脂抗体、抗β2糖蛋白-I和/或狼疮抗凝物)阳性,并自早孕期接受低剂量阿司匹林和预防性低分子肝素治疗。
  • 主要结局为活产,定义为妊娠22周后活产分娩;次要结局为伴或不伴严重特征的子痫前期、胎儿生长受限和死产。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiphospholipid syndrome is an autoimmune, hypercoagulable state that is caused by antiphospholipid antibodies. Anticardiolipin antibodies, anti-β2 glycoprotein-I, and lupus anticoagulant are the main autoantibodies found in antiphospholipid syndrome. Despite the amassed body of clinical knowledge, the risk of obstetric complications that are associated with specific antibody profile has not been well-established. OBJECTIVE: The purpose of this study was to assess the risk of obstetric complications in women with primary antiphospholipid syndrome that is associated with specific antibody profile. STUDY DESIGN: The Pregnancy In Women With Antiphospholipid Syndrome study is a multicenter, retrospective, cohort study. Diagnosis and classification of antiphospholipid syndrome were based on the 2006 International revised criteria. All women included in the study had at least 1 clinical criteria for antiphospholipid syndrome, were positive for at least 1 antiphospholipid antibody (anticardiolipin antibodies, anti-β2 glycoprotein-I, and/or lupus anticoagulant), and were treated with low-dose aspirin and prophylactic low molecular weight heparin from the first trimester. Only singleton pregnancies with primary antiphospholipid syndrome were included. The primary outcome was live birth, defined as any delivery of a live infant after 22 weeks gestation. The secondary outcomes were preeclampsia with and without severe features, intrauterine growth restriction, and stillbirth. We planned to assess the outcomes that are associated with the various antibody profile (test result for lupus anticoagulant, anticardiolipin antibodies, and anti-β2 glycoprotein-I). RESULTS: There were 750 singleton pregnancies with primary antiphospholipid syndrome in the study cohort: 54 (7.2%) were positive for lupus anticoagulant only; 458 (61.0%) were positive for anticardiolipin antibodies only; 128 (17.1%) were positive for anti-β2 glycoprotein-I only; 90 (12.0%) were double positive and lupus anticoagulant negative, and 20 (2.7%) were triple positive. The incidence of live birth in each of these categories was 79.6%, 56.3%, 47.7%, 43.3%, and 30.0%, respectively. Compared with women with only 1 antibody positive test results, women with multiple antibody positive results had a significantly lower live birth rate (40.9% vs 56.6%; adjusted odds ratio, 0.71; 95% confidence interval, 0.51-0.90). Also, they were at increased risk of preeclampsia without (54.5% vs 34.8%; adjusted odds ratio, 1.56; 95% confidence interval, 1.22-1.95) and with severe features (22.7% vs 13.8%, adjusted odds ratio, 1.66; 95% confidence interval, 1.19-2.49), of intrauterine growth restriction (53.6% vs 40.8%; adjusted odds ratio, 2.31; 95% confidence interval, 1.17-2.61) and of stillbirth (36.4% vs 21.7%; adjusted odds ratio, 2.67; 95% confidence interval, 1.22-2.94). In women with only 1 positive test result, women with anti-β2 glycoprotein-I positivity present alone had a significantly lower live birth rate (47.7% vs 56.3% vs 79.6%; P<.01) and a significantly higher incidence of preeclampsia without (47.7% vs 34.1% vs 11.1%; P<.01) and with severe features (17.2% vs 14.4% vs 0%; P=.02), intrauterine growth restriction (48.4% vs 40.1% vs 25.9%; P<.01), and stillbirth (29.7% vs 21.2% vs 7.4%; P<.01) compared with women with anticardiolipin antibodies and with women with lupus anticoagulant present alone, respectively. In the group of women with >1 antibody positivity, triple-positive women had a lower live birth rate (30% vs 43.3%; adjusted odds ratio,0.69; 95% confidence interval, 0.22-0.91) and a higher incidence of intrauterine growth restriction (70.0% vs 50.0%; adjusted odds ratio,2.40; 95% confidence interval, 1.15-2.99) compared with double positive and lupus anticoagulant negative women. CONCLUSION: In singleton pregnancies with primary antiphospholipid syndrome, anticardiolipin antibody is the most common sole antiphospholipid antibody present, but anti-β2 glycoprotein-I is the one associated with the lowest live birth rate and highest incidence of preeclampsia, intrauterine growth restriction, and stillbirth, compared with the presence of anticardiolipin antibodies or lupus anticoagulant alone. Women with primary antiphospholipid syndrome have an increased risk of obstetric complications and lower live birth rate when <1 antiphospholipid antibody is present. Despite therapy with low-dose aspirin and prophylactic low molecular weight heparin, the chance of a liveborn neonate is only 30% for triple-positive women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017. PMID: 28153662. doi:10.1016/j.ajog.2017.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。